Physician profile
Bo Wang
NPI 1053897892
$1,250.27
in general payments reported to CMS, 2019-2025
13 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $49.88 · 2023: $390 · 2024: $410 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.13 |
| Education | $198.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $339.04 | 2023 | Rybrevant, Erleada, Balversa |
| Regeneron Healthcare Solutions, INC. | $196.73 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $195.62 | 2023-2024 | Rinvoq |
| Daiichi Sankyo INC. | $137.36 | 2025 | Enhertu |
| Janssen Biotech, INC. | $116.86 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $82.67 | 2025 | |
| Emd Serono, INC. | $49.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.10 | 2024 | Gilotrif |
| Lilly USA, LLC | $38.08 | 2025 | |
| Eisai INC. | $22.04 | 2024 | |
| Amgen INC. | $16.96 | 2025 | Otezla |
| Organon LLC | $7.93 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.